The global landscape for treating rare genetic disorders is shifting rapidly, with the Fabry disease drug industry at the forefront of this evolution. Fabry disease is a rare X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A, leading to the accumulation of lipids in various organs. https://www.databridgemarketresearch.com/reports/global-fabry-disease-drug-market